Tolerance and efficacy of praziquantel in phase II A and II B therapeutic trials in Zambian patients.
D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D012548:Schistosoma haematobium; D012552:Schistosomiasis / Q000188:drug therapy*; D013997:Time Factors; D015024:Zambia
D007546:Isoquinolines; D011223:Praziquantel